ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/U5cZVlgAka #Rheumatology #ILD #RNL2026 https://t.co/LidiS3Wj9d

Italian retrospective study 411 IIM pts classified cancer risk per IMACS criteria: 44% high-, 38% intermed- 18% standard-risk. 9.2% had CA w/in 3yrs. Signif more in high-risk (OR 4.05). CA predictors: TIF1γ (OR  12.3), SAE1 (OR = 11.9) https://t.co/j4gA0g79bI https://t.co/Pt5nMs89bl

COMMON - Incidental Rotator Cuff Abnormalities on MRI In this cross-sectional study of 602 Finnish adults undergoing bilateral shoulder magnetic resonance imaging (MRI) and clinical assessment, abnormalities were found in nearly everyone over age 40 years, regardless of whether https://t.co/2n58lglVP0

Advanced Practice Rheum: Methotrexate In this session, we're going to review methotrexate. It is the most popular of disease-modifying drugs used in rheumatology. While it may be indicated for a few disorders, it's widely used in many inflammatory and autoimmune disorders. https://t.co/RKh3mQv7Hx

Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://t.co/XeBc4DJon9 https://t.co/n2wAq2OIGt

Hopkins Myositis study of 637 dermatomyositis pts - FLARES were assoc w/ DM Dz activity; manifest as rash (76%), motor weakness (58%), Pulm (19%), arthritis (12%). O nly 2–5% of Flare pts had cancer Dx w/in 6–24-mos https://t.co/AKC9oIKAS7 https://t.co/26q8FfkUfl

Among neuro-ophthalmic complications of Immune Checkpoint Inhibitors, myasthenia gravis (often with concomitant myositis) is most common irAE, followed by optic neuropathy (often as optic neuritis) https://t.co/7pxqSKY3M1 https://t.co/bisbShFHIc

Predictors of Calcinosis Cutis in Systemic Sclerosis Calcinosis cutis (CaC) is a common and disabling non-lethal manifestation in systemic sclerosis (SSc). This study used SSc patients from the EUSTAR database to clinically characterize patients and identify risk factors for https://t.co/uXbcCa04Lv

VEXAS Syndrome - A Review Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies. https://t.co/Nik0TJm6Qu https://t.co/WS35PRnbBv

Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z https://t.co/yEgB6ImDTi

5 yr Italian study of hospitalized autoimmune pts(2018-23) 4,896 IMID pts compared to 301,126 non-IMIM. IMID had signif higher risk cancer (adj OR 1.32) highest 1st yr. Decreased from 1.83 @ yr 1 to 1.2 @5+ yrs. IMID had more lung & bladder CA, leukemia lymphoma & melanoma https://t.co/UXqDHQtzv0

From 2015 to 2023, long-term opioid therapy declined in the USA. Approximately 4 million to 5 million patients were prescribed long-term opioid therapy in 2023. Long term opioid use remains a challenge https://t.co/N5s7mYvXSw https://t.co/YHdTbHLB4q

Claims data 2,751 #AAV patients - 6.2% developed #PJP infx. w/ predictors: age, max GC dose, rituximab, CTX, & PJP prophylaxis had Good concordance (0.70) @2mos & 0.66@1yrs. W/ monthly risk of 1.0%, prophylaxis yielded 34 potentially preventable PJP cases https://t.co/c2ObDnmfYp https://t.co/Ljr5maHZcr

Single-centre retrosp study of established 257 PMR pts. 98 referred by GPs were for Dx uncertainty (51 vs 14%), less for relapse (27%) or recurrence (11%). PMR Dx accuracy better by Rheums vs PCPs (83% v 62%, P < 0.05) https://t.co/DvTKeuGa4Q https://t.co/wQDXR46k5F

CDC: In 2023, age-adjusted prevalence of U.S. adults (>20 yrs) with obesity was 40.3% (9.7% with severe obesity; 31.7% overweight). BMI data from NHANES, & the National Center for Health Statistics https://t.co/kH9ajbUJ2m https://t.co/utbGWf4D12